Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
GLUE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.65
vs -0.51
Q2.23
N/A
-0.71
vs -0.57
Q3.23
N/A
-0.70
vs -0.58
Q4.23
N/A
-0.58
vs -0.63
Q1.24
N/A
-0.53
vs -0.65
Q2.24
N/A
-0.43
vs -0.71
Q3.24
N/A
-0.29
vs -0.70
Q4.24
+140%
0.23
vs -0.58
Q1.25
N/A
-0.40
vs -0.53
Q2.25
N/A
-0.42
vs -0.43
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
8.8M vs NA
Q1.24
NA
1.1M vs NA
Q2.24
NA
4.7M vs NA
Q3.24
NA
9.2M vs NA
Q4.24
+593%
60.6M vs 8.8M
Q1.25
+993%
11.6M vs 1.1M
Q2.25
+148%
11.6M vs 4.7M
Return on Equity
QoQ
Q1.23
-12%
-0.12
vs -0.11
Q2.23
-16%
-0.16
vs -0.12
Q3.23
-19%
-0.19
vs -0.16
Q4.23
-19%
-0.19
vs -0.19
Q1.24
-21%
-0.21
vs -0.19
Q2.24
-13%
-0.13
vs -0.21
Q3.24
-12%
-0.12
vs -0.13
Q4.24
+6%
0.06
vs -0.12
Institutionnal Ownership
QoQ
Q1.23
71
71
vs 69
3%
Q2.23
70
70
vs 71
-1%
Q3.23
75
75
vs 70
7%
Q4.23
79
79
vs 75
5%
Q1.24
71
71
vs 79
-10%
Q2.24
77
77
vs 71
8%
Q3.24
84
84
vs 77
9%
Q4.24
108
108
vs 84
29%
globenewswire.com
7 hours ago
zacks.com
9 hours ago
zacks.com
11 hours ago
seekingalpha.com
12 hours ago
Relative Strength
GLUE
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
-23%2025-Revenue
-799%2025-EPS
87%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
Wedbush
initialisePrevious: Not converted
2024-02-15
Now: Outperform
Wells Fargo
upgradePrevious: Not converted
2023-01-03
Now: Overweight
Credit Suisse
initialisePrevious: Not converted
2022-04-28
Now: Neutral
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.16Â ( -3.07%)
Relative Strenght
23
Volume Buzz
-46%
Earning Acce
Yes
Dist 52w H.
59%